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Vaccine adjuvants are compounds that enhance host immune responses to co-administered antigens in vaccines. Vaxjo is a web-
based central database and analysis system that curates, stores, and analyzes vaccine adjuvants and their usages in vaccine devel-
opment. Basic information of a vaccine adjuvant stored in Vaxjo includes adjuvant name, components, structure, appearance,
storage, preparation, function, safety, and vaccines that use this adjuvant. Reliable references are curated and cited. Bioinformatics
scripts are developed and used to link vaccine adjuvants to diﬀerent adjuvanted vaccines stored in the general VIOLIN vaccine
database. Presently, 103 vaccine adjuvants have been curated in Vaxjo. Among these adjuvants, 98 have been used in 384 vaccines
stored in VIOLIN against over 81 pathogens, cancers, or allergies. All these vaccine adjuvants are categorized and analyzed based
on adjuvant types, pathogens used, and vaccine types. As a use case study of vaccine adjuvants in infectious disease vaccines, the
adjuvants used in Brucella vaccines are speciﬁcally analyzed. A user-friendly web query and visualization interface is developed for
interactive vaccine adjuvant search. To support data exchange, the information of vaccine adjuvants is stored in the Vaccine Onto-
logy (VO) in the Web Ontology Language (OWL) format.
1.Introduction
Vaccines are one of the most eﬀective preventative health
tools available against infectious diseases, cancer, allergy, and
autoimmune diseases. Vaccination aims to generate a strong
immune response to the administrated antigen and provide
long-termprotectionagainstadisease.Frequently,usingonly
the antigen is not enough to stimulate that protective immu-
nity. Vaccine adjuvants are compounds that enhance the spe-
ciﬁc immune responses against coadministered antigens in
vaccines [1, 2]. The word adjuvant comes from the Latin
word adjuvare, meaning to help or to enhance. The term
“adjuvant” was coined by Ramon in the 1920s when they ob-
served that the injection of the diphtheria toxoid along with
unrelated substances in horses developed an abscess at the
injection site and generatedhigher speciﬁc antibody titers [3,
4]. In 1926, Glenny et al. demonstrated the adjuvant activity
of aluminum compounds with diphtheria toxoid absorbed
to alum [5]. In 1936, Freund’s complete adjuvant (FCA), an
emulsion of water and mineral oil containing killed myco-
bacteria, was developed [6]. Freund’s incomplete adjuvant
(FIA) that does not have the mycobacteria is less toxic and
has been used in many human vaccine formulations [7]. In
the 1950s, lipopolysaccharides (LPSs) from Gram-negative
bacteria were found to exhibit adjuvant activity [8]. In 1974,
muramyldipeptide (MDP) was found to be a mycobacterial
componentwithadjuvantactivityinFCA[9].Thereisawide
array of adjuvants that are being developed and used, from
a variety of sources. Currently, several hundred natural and
synthetic compounds are known to have adjuvant activity2 Journal of Biomedicine and Biotechnology
[1, 10]. However, the adjuvants that are permitted in licensed
vaccines are limited. In the US, alum salts and AS04 (which
is composed of aluminum salt and MPL) are licensed for use
in humans [11].
Adjuvants can function as immunostimulants, vehicles,
and carriers. Cox and Coulter summarize ﬁve modes of ac-
tion of vaccine adjuvants: (1) immunomodulation: the abil-
ity of many adjuvants to modify the cytokine network. (2)
Presentation: the ability of an adjuvant to preserve the con-
formational integrity of an antigen and to present the anti-
g e nt oa p p r o p ri a t ei m m u n ee ﬀector cells. (3) CTL induction:
induction of CD8+ cytotoxic T-lymphocyte (CTL) res-
ponses. (4) Targeting: the ability of an adjuvant to deliver an
immunogen to immune eﬀector cells, generally via antigen
presentation cells (APCs). (5) Depot generation: generation
of a short-term or long-term depot to give a continuous or
pulsed release [12]. The use of vaccine adjuvants allows for
a reduction in the number of immunizations or the amount
of antigen needed for immunization [13]. Vaccine adjuvants
can be administered either parenterally or mucosally.
VIOLIN (http://www.violinet.org/), primarily developed
by our group, is the ﬁrst web-based comprehensive vaccine
database and analysis system that targets for vaccine research
[14]. Currently, VIOLIN has included more than 2,800 vac-
cinesforover170infectiousdiseasesandmanynoninfectious
diseases (e.g., cancers and allergies). Here, a vaccine includes
a licensed vaccine or a vaccine construct that is not licensed
but has been shown to induce signiﬁcant protection against
a disease in at least one laboratory animal model. Many of
these vaccines use vaccine adjuvants. Therefore, it is impor-
tant to classify them and analyze their diﬀerential applica-
tions in vaccine development. However, the original VIOLIN
database did not support classiﬁcations of various vaccine
adjuvants or provide detailed vaccine adjuvant information.
Whileintensiveresearchhasbeenconductedandresulted
in identiﬁcation of many vaccine adjuvants, there is no web-
based central resource that allows storage, annotation, com-
parison, and analysis of vaccine adjuvants and their usages
in vaccine development. To address this challenge, we have
developed Vaxjo (http://www.violinet.org/vaxjo/), a web-
based vaccine adjuvant database and analysis system. Vaxjo
storestheinformationofmanuallycuratedvaccineadjuvants
and their applications in vaccine development. It also allows
bioinformatics analysis and comparison of various vaccine
adjuvants. Vaxjo is publically available at http://www.violinet
.org/vaxjo/.
2. Methods
2.1. Vaxjo System and Database Design. Vaxjo is implement-
ed using a three-tier architecture built on two HP ProLiant
DL380 G6 servers, which run the Redhat Linux operating
system (Redhat Enterprise Linux ES 4). Users can submit
database or analysis queries through the web. These queries
are then processed using PHP/SQL (middle-tier, application
server based on Apache) against a MySQL (version 5.0) rela-
tional database (back-end, database server). The result of
each query is then presented to the user in the web browser.
In addition, Vaxjo data curators and reviewers can also sub-
mitandreviewcuratedvaccineadjuvantdatathroughaweb-
based Vaxjo data curation system. Two servers are scheduled
to regularly backup each other’s data. Vaxjo is an integrated
program of the VIOLIN vaccine database and analysis [14].
Figure 1 demonstrates the Vaxjo workﬂow and system
design.Foreachspeciﬁcvaccineadjuvant,theVaxjodatabase
contains the following information: (1) detailed reference
citation information, for example, authors, journal, title,
year, volume, issue, and pages. These references are typi-
cally obtained from PubMed (http://www.ncbi.nlm.nih.gov/
pubmed) and used to obtain reliable information for vaccine
adjuvants. (2) General information of vaccine adjuvants, for
example, alternate names, description, stage of vaccine ad-
juvant development (e.g., preclinical, clinical stage, or li-
censed), components, preparation, safety, and so forth. This
information is manually curated and not available in the
general VIOLIN vaccine database originally developed [14].
The manual curation of peer-reviewed journal articles em-
phasizes the retrieval of vaccine adjuvant information and
experimental data associated with vaccine adjuvants. Using
an internal script, all the vaccines that are stored in VIOLIN
and use a speciﬁc vaccine adjuvant can be retrieved and dis-
played in Vaxjo searching page. A unique Vaccine Ontology
(VO) identiﬁer has been assigned to each vaccine adjuvant.
The VO IDs used in both the Vaxjo database and the general
VIOLIN vaccine database are used as primary keys for link-
ingthesetwodatabases.Thisprogramallowsadvancedquery
and comparison between diﬀerent vaccine adjuvants and
vaccines that use these adjuvants.
2.2. Semiautomatic Annotation of Vaccine Adjuvant Informa-
tion. A semiautomatic Vaxjo annotation system is developed
for vaccine adjuvant curation and analysis by modifying an
in-house web-based literature mining and curation system
called Limix [14–16]( Figure 2). The interactive Limix data
submission and review system (a) allows a data curator to
search literature, copy and edit text, and submit data to data-
base and (b) provides user-friendly tools for a data review-
er to review, edit, and approve the curated data on a com-
prehensive web interface. Upon approval after the critical
review by a reviewer, the curated data submitted by a curator
will be posted publicly. Limix also features automated
reference tracking and management using a version control
mechanism similar to that used in Wikipedia (http://www
.wikipedia.org/). The system stores all the history changes
made to every vaccine adjuvant. A reviewer can compare any
twoofthehistoryversionstotracethedetailedchangesmade
to a vaccine adjuvant. Figure 2 provides a more detailed view
of the Limix curation process and reviewing features.
Vaxjo is updated automatically when additional vaccine
adjuvants are added. All vaccine adjuvant updates can be
found and queried in the Vaxjo website.
2.3. Vaxjo Data Exchange, Transfer, and Download. To facili-
tate data exchange and transfer, the information of vaccine
adjuvants in Vaxjo is now stored in the Vaccine Ontol-
ogy (VO; http://www.violinet.org/vaccineontology/)[ 17].Journal of Biomedicine and Biotechnology 3
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Figure 1: Vaxjo workﬂow and system design. Manual curation includes peer-reviewed publications from PubMed. A PubMed ID (PMID) is
extracted and used by an internal script to retrieve detailed citation information (e.g., authors, journal, and date). The detailed information
of a vaccine adjuvant is curated and cited from published studies. Each vaccine adjuvant is assigned with a Vaccine Ontology (VO) ID, which
is further used in an internal computational script to obtain the information of relevant adjuvanted vaccines from the general VIOLIN
relational database.
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Figure 2: Submission and review processes of vaccine adjuvants into Vaxjo. (a) Selecting an adjuvant from a dropdown list or adding a new
adjuvant by entering the name in the ﬁeld below the dropdown list. (b) Vaxjo submission page, where each section is edited via a popup
dialog box that also provides options to insert references when needed. The bottom section of the Vaxjo curation web page includes detailed
reference information for a curator to review. (c) Review page. Vaxjo curators review information curated into Vaxjo and, after review,
submit the page for publication in Vaxjo.4 Journal of Biomedicine and Biotechnology
Table 1: Curated vaccine adjuvants used in at least ﬁve vaccines curated in VIOLIN.
Adjuvant type (number of adjuvants) Adjuvants with >5 vaccines in VIOLIN Number of vaccines
Mineral salts (13) 154
Alhydrogel 13
Aluminum hydroxide vaccine adjuvant 62
Aluminum phosphate vaccine
adjuvant 50
Aluminum potassium sulfate adjuvant 6
Aluminum vaccine adjuvant∗ 14
Emulsions (15) 118
Freund’s complete adjuvant 42
Freund’s incomplete adjuvant 42
Montanide ISA 720 adjuvant 6
Ribi vaccine adjuvant 11
Microorganism-derived (18) 73
Cholera toxin 17
Cholera toxin B subunit 6
CpG DNA vaccine adjuvant 12
LTR192G vaccine adjuvant 6
MPL adjuvant 10
Synthetic adjuvant (28) 28
Cytokines as adjuvants (9) 20
IL-12 vaccine adjuvant 9
Tensoactive compounds (5) 12
Quil-A vaccine adjuvant 5
Combination vaccine adjuvants (6) 9
Particulate antigen delivery systems (9) 11
Carbohydrates (2) 1
Note: ∗shows those aluminum vaccine adjuvants that were used but without more speciﬁc details (e.g., using aluminum hydroxide).
The vaccine adjuvant data stored in VO is machine-readable
and can be used for various software programs for data ex-
change and transfer.
2.4. Vaxjo Data Query and Display. The programming lan-
guages PHP and HTML were primarily used to interact with
the backend Vaxjo relational database to obtain vaccine ad-
juvant information. Since Vaxjo has been integrated with the
general VIOLIN database system, the Vaxjo data query tool
is also able to query the general VIOLIN vaccine database to
obtain the information of vaccines that use speciﬁc vaccine
adjuvants. Meanwhile, the vaccine adjuvant information in
theVaccineOntology(VO)isqueriedusinginternalSPARQL
scripts. The VO IDs of diﬀerent vaccine adjuvants are used as
thegluethatlinksthevaccineadjuvantsintheVaxjodatabase
and the general VIOLIN vaccine database.
2.5. Bioinformatics Analysis of the Vaxjo Vaccine Adjuvant
Data. The vaccine adjuvants stored in Vaxjo and their appli-
cations in development of vaccines stored in the general
VIOLIN database were obtained using the web-based Vaxjo
query or through internal scripts. A systematic analysis was
conductedtoclassifyandcomparediﬀerentcharacteristicsof
vaccine adjuvants.
3. Results
3.1. Vaxjo Statistics. Vaxjo is a web-based relational database
and analysis system based on a classical three-tier architec-
ture design [15]. Currently, Vaxjo has included 103 vaccine
adjuvants. In total, 384 vaccines have been detected to use
these vaccine adjuvants. Occasionally, more than one vaccine
adjuvant is used in a single vaccine. These 384 vaccines are
developedagainstinfectionsof76pathogens,suchasBacillus
anthracis (anthrax), Brucella spp. (brucellosis), inﬂuenza
virus, and Plasmodium spp. (malaria). Vaxjo also stores 15
vaccine adjuvants that have been used for vaccine develop-
ment against many cancers and allergies.
3.2. Analyses of Vaxjo Vaccine Adjuvants Based on Vaccine
Adjuvant Types. With the establishment of the Vaxjo vaccine
adjuvant database, we were able to systematically analyze the
vaccine adjuvants and their usages in vaccine development.
Table 1 shows the types of vaccine adjuvants and lists thoseJournal of Biomedicine and Biotechnology 5
Table 2: Mineral salt adjuvants.
Adjuvant name Number of Vaccines Mechanism Route Licensed
Adjumer 1 Immunostimulant Either∗ No
Aluminum hydroxide vaccine adjuvant 62 Vehicle/immunostimulant Parenteral Yes∗∗
Aluminum phosphate vaccine adjuvant 50 Vehicle/immunostimulant Parenteral Yes
Alhydrogel 13 Vehicle/immunostimulant Either Yes
Aluminum vaccine adjuvant∗∗∗ 14 Vehicle/immunostimulant Parenteral Yes
Aluminum potassium sulfate adjuvant 6 Vehicle/immunostimulant Parenteral Yes
Amorphous aluminum
hydroxyphosphate sulfate adjuvant
(AAHSA)
2 Vehicle/immunostimulant Parenteral Yes
Adjumer 1 Immunostimulant Either No
Calcium phosphate gel 1 Vehicle Parenteral In Europe
Calcium phosphate vaccine adjuvant 1 Vehicle Parenteral In Europe
DOC/Alum complex 1 Vehicle/immunostimulant Parenteral No
Rehydragel HPA 1 Vehicle Parenteral Yes
Rehydragel LV 1 Vehicle Parenteral Yes
Notes: ∗the term “either” means either mucosal or parenteral route. ∗∗the term “yes” means that this adjuvant is licensed in the USA. ∗∗∗shows those
aluminum vaccine adjuvants that were used but without more speciﬁc details (e.g., using aluminum hydroxide).
adjuvants which have ﬁve or more associated vaccines. The
adjuvant types are based on the derivation of the adjuvants
or the composition of the adjuvants. The largest numbers of
vaccine adjuvants are found in microorganism-derived adju-
vants (18), synthetic adjuvants (28), and mineral salt adju-
vants (13) (Table 1). If the numbers of vaccines using dif-
ferent adjuvants are considered, vaccine adjuvants based on
mineral salts, emulsions, and microorganism derivatives
have been used in 151, 115, and 73 vaccines, respectively
(Table 1). Aluminum hydroxide is the most common ad-
juvant found, with 62 associated vaccines collected in
VIOLIN. Freund’s complete and incomplete adjuvants are
also commonly used with each being associated with 42 vac-
cines. Although 28 synthetic adjuvants are curated in Vaxjo,
only 28 vaccines listed in VIOLIN use these synthetic adju-
vants.Onlytwoofthesesyntheticvaccineadjuvantscollected
in Vaxjo are not associated with any vaccines in VIOLIN.
Those commonly used vaccine adjuvants and their asso-
ciated vaccines are introduced below.
3.2.1. Salt-Based Vaccine Adjuvants. Mineral salt adjuvants
are commonly used as aluminum adjuvants that are ap-
proved for use in licensed vaccines. Table 2 lists the 13 min-
eral salt adjuvants in Vaxjo and displays their properties,
including the number of associated vaccines to each adju-
vant, mechanism of action, route of administration, and
whether or not the adjuvant is used in licensed vaccines. Of
the mineral salt adjuvants in Vaxjo, 10 are licensed for use in
vaccines either in Europe or the United States. Most mineral
salt adjuvants act as vehicles for antigens rather than as im-
munostimulants (Table 2).
Mineral salts, speciﬁcally aluminum salts, have been used
as adjuvants for decades and are therefore common in vac-
cine formulations [3, 13]. Alum salts have a depot eﬀect,
allowing the antigen to persist in the body so the immune
system can react to the antigen and facilitate uptake into
antigen-presenting cells (APCs). Aluminum also enhances
the antigenicity of some vaccines such as diphtheria and
tetanus toxoids [18]. Aluminum-adsorbed diphtheria and
t e t a n u st o x o i d sa r em o r ee ﬀective than plain ﬂuid toxoids in
primary immunization of children. However, there is little
diﬀerence between plain and adsorbed toxoids for booster
immunization [19]. Immune responses to proteins adju-
vanted with alum tend to be a T helper cell type 2 (Th2)
response[20].TheChapter21oftheUSCodeofFederalReg-
ulations (610.15(a)) limits the amount of aluminum in hu-
man vaccines to 0.85mg/dose. The majority are parenterally
used, rather than mucosally. The amount of an aluminum
adjuvant in vaccines currently licensed in the US ranges
from 0.125 to 0.85mg/dose [19]. In more than six decades,
aluminum vaccine adjuvants usually do not induce serious
adverse eﬀects. However, they often induce local reactions
such as redness, swelling, and tenderness at the injection site.
Occasionally, aluminum adjuvants were found to be associ-
ated with severe local reactions such as erythema, subcuta-
neous nodules, and contact hypersensitivity [19].
3.2.2. Emulsion-Based Vaccine Adjuvants. Emulsion based
adjuvants are oil-in-water or water-in-oil emulsions, which
work to enable slow release of an antigen at the injection
site. Fourteen emulsion-based vaccine adjuvants have been
curated and stored in Vaxjo (Table 3). With the exception
of the nanoemulsion vaccine adjuvant [21], all the emulsion
adjuvants in Vaxjo are delivered via the parenteral route.
Nanoemulsion vaccine adjuvant is delivered mucosally [21].
Water-in-oil emulsion adjuvants turn to cause high levels of
reactogenicity. Oil-in-water emulsion adjuvants turn to have
a low reactogenicity proﬁle. MF59 and AS03 are two licensed6 Journal of Biomedicine and Biotechnology
Table 3: Emulsion adjuvants.
Adjuvant name Number of vaccines Mechanism Route Licensed
Freund’s complete adjuvant 42 Immunostimulant Parenteral No
Freund’s incomplete adjuvant 42 Vehicle Parenteral No
Ribi vaccine adjuvant 11 Immunostimulant Parenteral No
Montanide ISA 720 adjuvant 6 Vehicle Parenteral No
Nanoemulsion vaccine adjuvant 3 Immunostimulant Mucosal No
TiterMax gold adjuvant 3 Immunostimulant Parenteral No
AF03 1 Immunostimulant Parenteral No
AS03 1 Immunostimulant Parenteral Licensed
MF59 1 Vehicle Parenteral In Europe
Montanide incomplete seppic adjuvant 1 Vehicle Parenteral No
Montanide ISA 51 1 Vehicle Parenteral No
Specol 1 Immunostimulant Parenteral No
SPT (antigen formulation) 1 Vehicle Parenteral No
Squalene-based adjuvants 1 Vehicle Parenteral No
TiterMax gold adjuvant 3 Immunostimulant Parenteral No
oil-in-water emulsion adjuvant used in humans. MF59 is not
toxic and prepared with a low content of squalene (4.3%
w/w), a biodegradable oil naturally found in plants and
animals including humans. In humans, squalene is an inter-
mediate organic compound in the steroid hormone biosyn-
thetic pathway and is a direct synthetic precursor to choles-
terol.MF59induceslowreactogenicityatthesiteofinjection.
MF59isabletoinducefastprimingofantigen-speciﬁcCD4+
T-cell responses and to induce strong and long-lasting mem-
ory T- and B-cell responses [22]. MF59 has been licensed in
more than 20 countries for more than 14 years. It has been
used in many licensed vaccines such as Fluad, Focetria, and
Aﬂunov. AS03 (for “Adjuvant System 03”) is another squa-
lene-based immunologic adjuvant used in various vaccine
products by GlaxoSmithKline (GSK). AS03 is used, for ex-
ample, in GSK’s A/H1N1 pandemic ﬂu vaccine Arepanrix
H1N1.
3.2.3. Microorganism-Based Vaccine Adjuvants. Microorgan-
ism-based vaccine adjuvants are adjuvants that are derived
from microorganisms. Bacteria have an abundance of capac-
ity for stimulating the immune system, and the adjuvants
derived from bacteria are abundant. As whole bacteria are
generally too toxic to use as an adjuvant, many bacterium-
derived vaccine adjuvants are derived from parts of bacteria
[1]. Table 4 displays the properties of the 18 microorganism-
based adjuvants in Vaxjo. Only two of the microorganism-
based adjuvants are licensed: MPL licensed in the United
States as part of the AS04 adjuvant formulation [23], and
Bordetella pertussis component vaccine adjuvant [24] that
is used in several licensed vaccines. Microorganism-derived
adjuvants cholera toxin and MPL are used in 17 and 10 vac-
cines, respectively. Many microorganism-derived adjuvants
arebasedonmicrobialnucleicacids.Forexample,CpGDNA
is the unmethylated CpG dinucleotides in what is called
motifs, which are abundant in microbial DNA, but not in the
DNA of vertebrates [25]. CpG DNA is immunostimulants
that have the ability to activate Th1 immunity [26].
All but one microorganism-derived adjuvants act as
immunostimulants as their mechanism of action. Adjuvants
derived from the toxins of bacteria are used to stimulate mu-
cosal immunity, which is important for protecting against
many pathogens that are contracted mucosally [27]. The
route of administration is able to reveal what type of immu-
nity the adjuvant can stimulate, with eight microorganism-
derived adjuvants being mucosally administered (generally
intranasally). These are adjuvants which can help to stim-
ulate mucosal immunity which is often critical in inducing
protectionfrompathogensthatarecontractedmucosally.Six
of the adjuvants are administered both parenterally and mu-
cosally, and ﬁve are parenterally administered (Table 4).
3.2.4. Other Vaccine Adjuvants. The other six adjuvant types
are synthetic adjuvants, cytokine adjuvants, particulate anti-
gen delivery systems, carbohydrate vaccine adjuvants, ten-
soactive compounds, and combination vaccine adjuvants
(Table 1).
Synthetic adjuvants are synthetically made compounds
that mostly are utilized as immunostimulants and occasion-
ally act as carriers. There are 28 synthetic adjuvants in Vaxjo.
Some are derived to mimic bacterial components (Table 1).
For example, muramyl dipeptide (MDP) is formulated to
imitate a component found in the cell walls of mycobacteria
used in Freund’s complete adjuvant [28]. In addition, many
synthetic MDP analogs are used as vaccine adjuvants. Admi-
nistration routes are diverse, as there are parenterally, mu-
cosally, and also topically administered synthetic vaccine ad-
juvants.
Cytokines, signaling molecules of the immune system,
are also used as adjuvants to elicit a speciﬁc immuneJournal of Biomedicine and Biotechnology 7
Table 4: Microorganism-derived adjuvants.
Adjuvant name Number of Vaccines Mechanism Route Licensed
Cholera toxin 17 Immunostimulant Mucosal No
CpG DNA vaccine adjuvant 12 Immunostimulant Either ∗ No
MPL adjuvant 10 Immunostimulant Either As part of AS04
Cholera toxin B subunit 6 Immunostimulant Mucosal No
LTR192G vaccine adjuvant 6 Immunostimulant Mucosal No
Bordetella pertussis component vaccine
adjuvant 3 Immunostimulant Parenteral Yes
E. coli heat-labile toxin, LT 3 Immunostimulant Mucosal No
CTA1-DD gene fusion protein 2 Immunostimulant Either No
Etx B subunit adjuvant 2 Immunostimulant Either No
Killed Corynebacterium parvum vaccine
adjuvant 2 Immunostimulant Parenteral No
Lipopolysaccharide vaccine adjuvant 2 Immunostimulant Either No
LTK63 vaccine mutant adjuvant 2 Immunostimulant Mucosal No
Corynebacterium-derived P40
vaccine adjuvant 1 Immunostimulant Parenteral No
Flagellin vaccine adjuvant 1 Immunostimulant Either No
LTK72 vaccine adjuvant 1 Immunostimulant Mucosal No
MPL-SE vaccine adjuvant 1 Immunostimulant Parenteral No
Non-toxic mutant E112K of Cholera Toxin
mCT-E112K 1 Immunostimulant Mucosal No
Ty particles vaccine adjuvant 1 Vehicle Parenteral No
Note: ∗either means either mucosal or parenteral route.
response [23]. There are nine cytokines as adjuvants in Vaxjo
(Table 1). For example, granulocyte-macrophage colony-
stimulating factor (GM-CSF), a cytokine that activates
mature granulocytes and macrophages, is being used as an
adjuvant for Hepatitis B in immunocompromised patients
[29]. The GM-CSF adjuvant is also used in vaccines for
HIV and cancer [30, 31]. Currently, none of cytokine-based
adjuvants are licensed.
Particulate antigen delivery systems are adjuvants that
have a depot eﬀect for the antigen and include liposomes,
polymeric microspheres, virus-like particles, and immunos-
timulating complexes (ISCOMs) [13]. There are nine partic-
ulate antigen delivery systems in Vaxjo. These adjuvants act
asvehiclesfortheantigen,whileoftenalsocontainingimmu-
nostimulating compounds. They are parenteral adjuvants.
Liposome-based adjuvants consist of spheres formed by lipid
layers that can encapsulate antigens and thus act both as
a vehicle and an immunostimulant [1]. Six liposome-based
vaccine adjuvants are listed in Vaxjo. MTP-PE liposomes are
liposomes that contain a synthetic analog of MDP, MTP-PE.
It is used in vaccines for hepatitis B and herpes simplex virus
[32, 33].
Carbohydrateadjuvantsareadjuvantscomposedofcom-
plex carbohydrates of natural origin that stimulate the im-
mune system. The main sources of these carbohydrates are
plants and fungi [1]. For example, gamma inulin is a car-
bohydrate derived from the root of plants of the Compositae
family. Gamma inulin is an activator of humoral and cellular
immunity as well as the alternate complement pathway [1].
Two carbohydrate adjuvants are curated in Vaxjo (Table 1).
They are generally parenterally administered and are immu-
nostimulating adjuvants.
Tensoactive compounds are surfactants or active surface
agents. They are immunostimulating adjuvants generally de-
rived from plants, namely, Quillaja saponaria. There are ﬁve
tensoactive adjuvants in Vaxjo (Table 1). Most saponins are
considered too toxic for human use, although Quil A has
been used in animals [1]. The saponins act as a vehicle/im-
munostimulant and are parenterally administered.
Combination vaccine adjuvants include two or more dif-
ferent adjuvants that are used in combination. Examples of
combination adjuvants include adjuvants such as AS04 and
Algammulin. There are six such adjuvants in Vaxjo (Table 1).
These adjuvants combine diﬀerent mechanisms of action
from two or more adjuvants [13]. For example, AS04, a li-
censed vaccine in the United States, is a combination of alu-
minum and MPL [34]. Alum and MPL complement one
another: Alum provides signals required for generating long-
lived memory cells, whereas MPL enhances the diﬀerentia-
tion of cytotoxic T lymphocytes (CTL) [35].
3.3. Analysis of Vaccine Adjuvants Based on the Pathogen
Types. Table 5 displaysadjuvantedvaccinesbypathogen/dis-
ease types and vaccine types. Of the pathogens/diseases in
VIOLIN, 46.2% have vaccines that use adjuvants. Gram-pos-
itive pathogens and parasites are associated with a high per-
centage of adjuvanted vaccines, with 79% and 71% of species8 Journal of Biomedicine and Biotechnology
Table 5: Vaccines with adjuvants by vaccine-targeted pathogens or diseases.
Pathogen or
disease
Number of
pathogen species
Subunit
vaccines
Toxoid
vaccines
DNA
vaccines
Conjugate
vaccines
Live
vaccines
Killed
vaccines
RCV
vaccine∗∗ VDP∗∗∗ Total
Gram+ bacteria 11/14∗ 39 26 2 6 0 4 1 18 96
Gram− bacteria 22/48 96 6 2 7 0 2 5 13 130
Viruses 27/87 43 0 5 0 2 19 1 13 83
F u n g i 1 / 1 3 0 0 00000 3
Parasite 15/21 50 0 1 0 1 1 2 0 55
Cancer — 11 0 1 0 1 0 0 0 13
A l l e r g y — 1 0 1 00000 2
Total 80/173 245 32 14 13 4 26 9 44 384
∗11/14 means 11 out of 14 spp. that have adjuvanted vaccines. Other numbers in this column use the same representation.
∗∗RCV stands for recombinant vector vaccine.
∗∗∗ VDP stands for vaccine made with diﬀerent preparation methods, including (1) vaccine containing subunit component and inactivated whole organism,
(2)vaccinecontainingDNA vaccinefor primingand subunit vaccinefor boosting,and(3)vaccinecontainingDNA vaccinefor primingandAdvectorvaccine
for boosting.
containing adjuvanted vaccines, respectively. Meanwhile,
45.8% of Gram-negative pathogen vaccines use adjuvants.
Of 1,982 viral vaccines in VIOLIN, only 4% are adjuvanted.
For the cancer and allergy vaccines in VIOLIN, 20.83% use
adjuvants. 13% of all the vaccines in VIOLIN are adjuvanted.
Todevelopvaccinesforaspeciﬁcpathogen,variousstrat-
egies, including diﬀerent vaccine adjuvants, may have been
used. The choice of using diﬀerent vaccine adjuvants may be
dependent on the type of protective immunity required for
the speciﬁc pathogen. As an example of illustrating these
points, here we summarize and compare all vaccine adju-
vants used in development of Brucella vaccines. Brucella,a
Gram-negative intracellular pathogen that causes brucellosis
in humans, is a disease for which there is no licensed human
vaccine. Although humoral immune response against Bru-
cella lipopolysaccharides (LPS) provides partial protection,
the cell-mediated immunity plays a major role in protection
against virulent Brucella challenge [36, 37]. In VIOLIN, 45
Brucella vaccines are curated. Of these 45 Brucella vaccines,
nine use adjuvants (Table 6). Among these nine vaccines, six
are subunit vaccines [38–42]. This phenomenon follows the
trend of subunit vaccines being the majority of vaccines that
useadjuvants.Among threeof thesesix subunitvaccines that
use Freund’s adjuvants, two of them use complete Freund’s
adjuvant for the primary immunization and incomplete Fre-
und’sadjuvantfortheboostvaccination[40,41].Threeother
vaccines are not categorized as subunit vaccines [43–45].
Among them is a vaccine that uses a DNA vaccine for prim-
ing and uses a recombinant protein adjuvanted by incom-
pleteFreund’sadjuvantforboosting[45].TheNPAPBrucella
vaccineisakilledvaccinethatusesFreund’sincompleteadju-
vant [43]. The recombinant O. anthropi expressing Brucella
Cu/Zn SOD is live vaccine that uses with CpG DNA adjuvant
[44]. The CpG DNA adjuvant is able to bias the immune res-
ponse to the Brucella antigen towards a cell-mediated immu-
nity.TherecombinantO. anthropi expressing BrucellaCu/Zn
SOD alone without the CpG DNA adjuvant is not able to
induce protection, indicating the importance of the cell-
mediated immunity in the protection induction [44].
Although most subunit vaccines use adjuvants, some
subunit vaccines do not use adjuvants. For example, two of
these Brucella subunit vaccines contain Brucella lipopolysac-
charide (LPS) as a primary antigen that can also perform as
an adjuvant-like function by inducing cell-mediated immu-
nity [46, 47]. The recombinant chimera vaccine BLSOmp31
includesaknownBrucellaOmp31-derivedprotectiveepitope
fused to Brucella lumazine synthase (BLS) [48]. The BLS is
highly immunogenic and functions as a scaﬀold protein and
a carrier for the foreign peptide [49].
3.4. Analysis of Vaccine Adjuvants Based on Vaccine Types.
The majority of adjuvanted vaccines, with 245 out of 384
vaccines (63.8%), are subunit vaccines. Other types of ad-
juvanted vaccines stored in VIOLIN include toxoid vac-
cines (8%), killed vaccines (7%), DNA vaccines (4%), and
conjugate vaccines (3%). Forty-three vaccines in VIOLIN
contain more than one adjuvant (http://www.violinet.org/
vaxjo/stat2.php). In many cases, a primary vaccination uses
one adjuvant, and then a boost immunization uses another
adjuvant. Alternatively, one vaccine includes more than one
adjuvant for one vaccination.
A subunit vaccine is composed of a puriﬁed protein(s)
or other antigenic determinant(s) from a disease-causing
organism. A subunit vaccine does not include pathogen
nucleic acids. The subunits have less risk of causing adverse
reactions. Subunit vaccines usually consist of speciﬁc pro-
teins targeted to generate protection; however, they are rarely
immunogenic on their own to trigger a response that will
generateprotection[50].Theverynatureofsubunitvaccines
generates a need for adjuvantation. The vast majority of vac-
cines using adjuvants are subunit vaccines, representing
63.8% of the adjuvanted vaccines in VIOLIN (Table 5). In
Vaxjo, 53 of the vaccine adjuvants are used in subunit vac-
cines. Most of these adjuvants have not frequently been used
and occur only in one or two vaccines. A few are used more
frequently, such as aluminum hydroxide, aluminum phos-
phate, Alhydrogel, Freund’s complete and incomplete adju-
vants, and cholera toxin.Journal of Biomedicine and Biotechnology 9
Table 6: Brucella vaccines with adjuvants in VIOLIN.
Vaccine name Vaccine type Adjuvant name Reference
B. melitensis DNA vaccine encoding Omp31 boosted with Omp31 DNA vaccine with
recombinant protein Incomplete Freund’s adjuvant [45]
B. melitensis P39 protein vaccine Subunit vaccine CpG DNA vaccine adjuvant [38]
Brucella ovis microparticle subunit vaccine Subunit vaccine Lipopolysaccharide adjuvant [39]
Brucella recombinant SurA protein vaccine Subunit vaccine
Incomplete Freund’s adjuvant
Complete Freund’s adjuvant [40]
E. coli Escheriosome-mediated cytosolic delivery of recombinant
Brucella rL7/L12 protein Subunit vaccine Complete Freund’s adjuvant [41]
NPAP Brucella vaccine Inactivated or “killed”
vaccine Incomplete Freund’s adjuvant [43]
Porin and S-LPS extracted from virulent Brucella abortus 2308 Subunit vaccine MPL vaccine adjuvant [42]
Recombinant Brucella DnaK protein vaccine Subunit vaccine
Incomplete Freund’s adjuvant
Complete Freund’s adjuvant [40]
Recombinant O. anthropi 49237SOD Recombinant vector
vaccine CpG DNA vaccine adjuvant [44]
The most frequently adjuvanted killed vaccines, with 19
out of 26, are viral vaccines (Table 5). Twelve adjuvants have
been used in killed vaccines, with the most frequently used
being aluminum hydroxide. The list of the US licensed vac-
cines that contain aluminum adjuvants include Anthrax vac-
cine, Hepatitis A and B vaccines, Rabies vaccine, Human
papillomavirus vaccine, Pneumococcal conjugate vaccine,
DTP (diphtheria-tetanus-pertussis vaccine) [19]. However,
licensed human inactivated Polio Virus (IPV) vaccine,
measles, mumps and rubella vaccine (MMR), varicella vac-
cine, and inﬂuenza vaccines do not contain any aluminum
salt vaccine adjuvant [50]. Some of the other adjuvants used
in killed vaccines in research are QuilA, aluminum phos-
phate, AS03, AS04, AF03, and Ribi vaccine adjuvant.
A toxoid vaccine consists of a toxoid (also called inacti-
vated toxin), which is a processed toxin that has been treated
by chemical means, heat, or irradiation and is no longer
capableofcausingdisease.Toxoid vaccines,whicharesimilar
to subunit vaccines, are also usually adjuvanted, typically
with aluminum. There are nine adjuvants associated with 32
toxoid vaccines (Table 5), which include aluminum adju-
vants, squalene, and nanoemulsion vaccine adjuvant. The
most frequently used is aluminum phosphate, which is used
in nine toxoid vaccines.
A conjugate vaccine is vaccine that conjugates/links anti-
gens to the molecules that form the outer coat of disease-
causing bacteria to promote an immune response. Conjugate
vaccines are not often adjuvanted, as they are usually immu-
nogenic enough to not need an adjuvant. However, there are
seven adjuvants in Vaxjo that are used in 13 conjugate vac-
cines (Table 5), including aluminum hydroxide, DDA, Ribi
vaccine adjuvant, and MPL.
Live vaccines generally do not need adjuvants as they are
rather immunogenic on their own. However, there are ﬁve
vaccine adjuvants in Vaxjo that are used in four live attenuat-
ed vaccines (Table 5). These include aluminum hydroxide,
Freund’s complete and incomplete adjuvants, DHEA vaccine
adjuvant, and Arlacel A. These three vaccines are for protec-
tion against Venezuelan equine encephalitis virus (VEE),
cancer, smallpox, and E. maxima. For these vaccines, the
adjuvant was given prior to immunization with the live
attenuated vaccine.
Similar to live attenuated vaccines, DNA vaccines are not
often adjuvanted. As for DNA vaccines, there are also eight
adjuvants used that are in Vaxjo. There are 14 DNA vaccines
that use adjuvants use GM-CSF, Resiquimod, and DDA
among others (Table 5).
3.5. Ontology-Based Vaccine Adjuvant Representation for
Exchange, Transfer, and Download of Vaccine Adjuvant Data.
The basic information of vaccine adjuvants in Vaxjo is now
stored in the Vaccine Ontology (VO; http://www.violinet
.org/vaccineontology/)[ 17]. A biomedical ontology is a set
of terms and relations that represent entities in a biomedical
domain and how they relate to each other. Ontology terms
are associated with documentation and deﬁnitions, which
are, ideally, expressed in formal logic in order to support
automated reasoning [51]. VO is a community-based ontol-
ogy in the vaccine domain. It is developed based on the Web
Ontology Language (OWL) format (http://www.w3.org/
TR/owl-ref/), which can be processed by many existing soft-
ware programs and used for Semantic Web applications. The
storage of vaccine adjuvants in VO allows development of
newsoftwareprogramstointegratethevaccineadjuvantdata
withotherbiomedicaldataandsupportfurtherbioinformat-
ics analyses.
Figure 3 provides an example of how a VO vaccine adju-
vantterm“aluminum vaccine adjuvant”is shownin VO.The
top level terms “entity → continuant → independent con-
tinuant → material entity” come from the Basic Formal
Ontology (BFO: http://www.ifomis.org/bfo/), which is a top10 Journal of Biomedicine and Biotechnology
Class hierarchy
(a)
Usage
(b)
Figure 3: Modeling and application of vaccine adjuvants in the Vaccine Ontology (VO). (a) The hierarchical structure of vaccine adjuvants
in VO. (b) All the vaccines that use this adjuvant. The usage information is obtained by a SPARQL query based on the logical deﬁnitions of
vaccines. The website that contains this information is http://purl.obolibrary.org/obo/VO 0000884.
(a)
(b)
(c)
(d)
Figure 4: An example of searching a vaccine adjuvant and its related information in Vaxjo. (a) The keyword “aluminum” is queried in Vaxjo.
(b) The adjuvants resulting from the Vaxjo keyword search. (c) The Vaxjo page obtained by clicking on “Aluminum vaccine adjuvant” in
(b). The Vaxjo page for the adjuvant has information about the adjuvant (alternate names, components, function, etc.) and lists vaccines in
which the adjuvant is used, as well as references. (d) The vaccine page obtained by clicking on the vaccine number shown in (b). This web
page shows the details about this vaccine.
ontologythatcoverstheuniversalentities.Acontinuant(e.g.,
apersonoraquality)isanentitythatexistsinfullatanytime.
An independent continuant (e.g., a person which is a mater-
ial entity, but not a quality) is a continuant that bears its
quality and is independent of other entities. All the other
terms in the hierarchy shown in Figure 3(a) are VO-speciﬁc
terms. As a part of a vaccine, a vaccine additive (e.g., pre-
s e r v a t i v ea n da d j u v a n t )i sam a t e r i a le n t i t yt h a ti sa d d e dt o
the immunogen of a vaccine. An aluminum vaccine adjuvant
is a mineral salt vaccine adjuvant, a common vaccine ad-
juvant type (Figure 3(a)). Figure 3(b) indicates all vaccines
that use this aluminum vaccine adjuvant (including all itJournal of Biomedicine and Biotechnology 11
child terms). One advantage of this OWL format is that it
can be parsed and read by many computer programs. The
machine readable feature supports automated reasoning.
3.6. Vaxjo Data Query and Display. The manually curated
and precomputed Vaxjo data can be eﬃciently queried and
visualized as demonstrated in Figure 4. The vaccine adjuvant
can be queried by specifying one or multiple criteria: (1) a
characteristic of a vaccine adjuvant, including name, alter-
native name, adjuvant VO ID, description, components, and
storage, (2) vaccine type, and (3) pathogen (Figure 4(a)).
All query hits are ﬁrst displayed on a web table containing
basic adjuvant information (Figure 4(b)). Individual vaccine
adjuvant can further be selected by a user to show more
detailed information (Figure 4(c)). The associated vaccines
are viewed by clicking on the number of associated vaccines
(Figure 4(d)).
4. Discussion
Vaxjo contains manually curated vaccine adjuvants that have
been used in a wide array of vaccines for a large variety of in-
fectious diseases, as well as diseases such as cancer
and allergies. To the best of our knowledge, Vaxjo is the ﬁrst
web-based, publically available database and analysis sys-
tem that targets for the curation and analysis of vaccine
adjuvants. There is a database of adjuvants/stimulants that is
part of a nonhuman primate HIV/SIV vaccine trials database
(http://www.hiv.lanl.gov/content/vaccine/adjuvants-stimu-
lants.html). However, this database focuses on adjuvants
used in HIV/SIV vaccine trials, which is a much narrower
focus than Vaxjo. While many adjuvant review papers also
exist [1, 2, 12, 13, 19, 50, 52], the information of vaccine
adjuvants introduced in these review papers cannot be
queried online and updated. The original VIOLIN database
also includes many vaccines using diﬀerent adjuvants. How-
ever, the general VIOLIN database does not include clas-
siﬁcation and details about each vaccine adjuvant. The Vaxjo
database and query system is unique in that Vaxjo integrates
the information of individual adjuvants and their uses in
development of different vaccines stored in the general
VIOLIN database. Therefore, Vaxjo is not just one simple ex-
tension of the VIOLIN vaccine database. The Vaxjo database
is a new and relatively independent program.
A few challenges have been identiﬁed throughout the
vaccine adjuvant curation process. One challenge is that
many adjuvants are proprietary, and therefore there is little
information available about them. There are many licensed
animal vaccines that reside in VIOLIN, that lack adjuvant
information. Because there is little information available on
these vaccines, it is possible that some of these vaccines are in
fact adjuvanted.
The Vaxjo database and analysis system can be used to
facilitate rational vaccine design. Many diseases are complex
intheirinteractionswiththehostimmunesystem,thusmak-
ing vaccine design diﬃcult. To induce a protective immunity
against a speciﬁc disease, an appropriate vaccine adjuvant is
often required. Due to the large number of adjuvants in the
market, it is often diﬃcult to decide which vaccine adjuvant
to use. The Vaxjo database provides details for each adjuvant
andho wtheyha v ebeenusedindev elopmentofeﬀectivevac-
cines against diﬀerent types of diseases. Therefore, an ef-
ﬁcient query, comparison, and analysis of the data stored in
Vaxjo allows a researcher to identify a small tailored list of
vaccine adjuvants that can be used for enhancing induction
of desired immune responses and having the highest possi-
bility of success.
As a central and vital source of vaccine adjuvants, Vaxjo
isatimelyrepositoryandisexpectedtohaveasigniﬁcantim-
pact for vaccine research and development.
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